TIDMGWP

RNS Number : 7216Z

GW Pharmaceuticals PLC

31 May 2016

GW Pharmaceuticals to Present at the Goldman Sachs 37(th) Annual Global Healthcare Conference and the Jefferies 2016 Healthcare Conference

London, UK, 31 May 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Goldman Sachs 37(th) Annual Global Healthcare Conference to be held at Terranea in Rancho Palos Verdes, California on 8 June, 2016 at 8:40 a.m. PDT and at the Jefferies 2016 Global Healthcare Conference at the Grand Hyatt Hotel in New York City on 9 June, 2016 at 4:00 p.m. EDT.

A live audio webcast of the presentations will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentations.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R) (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome and Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.

Enquiries:

 
 GW Pharmaceuticals plc              (Today) +44 20 3727 1000 
 Stephen Schultz, VP Investor        917 280 2424 / 401 500 
  Relations (U.S.)                    6570 
 
 FTI Consulting (Media Enquiries) 
 Ben Atwell / Simon Conway           +44 20 3727 1000 
 
   FleishmanHillard (U.S. Media) 
                                     212 453 2382 / 917 697 
 Paddi Hurley / Adam Silverstein      9313 
 
 Peel Hunt LLP (UK NOMAD) 
 James Steel                         +44 20 7418 8900

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCWGUBGAUPQUBG

(END) Dow Jones Newswires

May 31, 2016 07:00 ET (11:00 GMT)

Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Gw Pharmaceuticals Charts.
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Gw Pharmaceuticals Charts.